News & Research
New studies, trials, regulatory changes and news about the compounds on Amino Reference. Items are collected automatically once a day and summarised by AI; they are not reviewed by an editor before they appear here. Read the original source before relying on anything.
Last updated 2026-10-05.
- Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
Rapid Communications in Mass Spectrometry
A mass-spectrometry study reports how retatrutide, the compound this site lists as GLP3-R, can be detected in human plasma and urine and describes its excretion profile. The findings matter for sports-drug testing because they show the compound can be identified in biological samples.
- Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.
Nat Med
Nature Medicine published a randomized placebo-controlled trial of semaglutide in type 2 diabetes with kidney disease. This is primary human evidence and should set the kidney-benefit grade on the GLP1-S page.
- Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
N Engl J Med
The New England Journal of Medicine published a trial of once-weekly survodutide in adults with obesity and type 2 diabetes. That paper should be the lead human citation for efficacy and safety on the survodutide page.
- Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.
Lancet
Lancet published the phase 3 ACHIEVE-4 trial of cardiovascular safety for oral orforglipron versus insulin glargine in type 2 diabetes at higher cardiovascular risk. This is the primary citation for any heart-safety statement on the orforglipron page.
- Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.
Clin Obes
A systematic review pooled head-to-head studies of tirzepatide versus semaglutide for weight loss. Comparative wording on the GLP2-T and GLP1-S pages should follow this human evidence rather than cross-trial claims.
- Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort.
Hum Psychopharmacol
A 12-month real-world cohort tracked renal biomarkers and lithium safety after tirzepatide was started in people with bipolar disorder already on lithium. The GLP2-T safety section should cover this interaction setting and follow the signal the paper actually found.
- Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues.
BMJ Open
A EudraVigilance analysis examined tirzepatide reports tied to suboptimal outcomes and drug-use problems. The GLP2-T safety section should add any disproportionate real-world signals this paper actually identifies.
- Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.
Clin Obes
A systematic review and meta-analysis assessed depression burden and risk in people receiving semaglutide. The GLP1-S psychiatric safety text should be aligned to the pooled result instead of left as anecdote.
- Hemodynamic Compromise Due to Semaglutide-Associated Abdominal Distension.
JACC Case Rep
A case report describes hemodynamic compromise linked to semaglutide-associated abdominal distension. This is a rare safety signal and should be listed as a single case, not as an expected effect.
- Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging.
Aging Cell
A study reports that elamipretide rejuvenated oocyte quality and restored female fertility during reproductive aging. The listing does not state the model, so the SS-31 page should not add a human fertility benefit until that is confirmed.
- Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.
Diabetes Obes Metab
A paper reports nephroprotective effects of survodutide in hypertension-accelerated diabetic kidney disease. Confirm whether it is human or animal before it is allowed to change the kidney grade on the survodutide page.
- Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.
Contemp Clin Trials
A review covers the mechanism, clinical evidence, and open questions for survodutide in obesity. It is a check on what the page should still call uncertain, not a new trial result.
- Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
Diabetes Care
This paper estimates tirzepatide MACE benefit in SURPASS-CVOT by imputing a placebo from REWIND, rather than reporting a new outcome trial. The site should not present that estimate as direct evidence of cardiovascular benefit.
- Semaglutide Demonstrates Benefits Across Frailty Levels.
JAMA
JAMA reported that semaglutide showed benefits across frailty levels. If the GLP1-S page implies benefit is limited to healthier adults, this human report should be checked before that limitation is kept.